Figure 5.
Within-day variations in baseline, predose values of M30 and M65 antigens in plasma of ovarian cancer patients before treatment with Carboplatin. Two separate blood samples were obtained with a 1–8 h gap between collections. The percentage difference in the two results for each patient is presented in the graph. In these studies the M65 assay was used to determine the M65 antigen, while the M30 Apoptosense assay was used to determine the M30 antigen.
